Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ZNF215
REST API REST API
Homo sapiens
ZNF215 is differentially expressed in 181 experiments: 70 organism parts: cervix, heart, ... (68 more);, 130 disease states: normal, colon carcinoma, ... (128 more);, 64 cell types 415 cell lines 16 compound treatments and 72 other conditions.
Synonyms ZKSCAN11
Orthologs ZNF215 (Bos taurus)   ZNF215 (Canis familiaris)   (Compare orthologs)
InterPro Term Znf_C2H2-like, Znf_C2H2, Krueppel-associated_box, Tscrpt_reg_SCAN
Gene Ontology Term DNA binding, regulation of transcription, DNA-dependent, intracellular, transcription, DNA-dependent, metal ion binding, nucleic acid binding, nucleus, zinc ion binding, viral reproduction, sequence-specific DNA binding transcription factor activity
UniProt Accession Q9UL58, Q96C84
Search EB-eye ENSG00000149054
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-MTAB-24, E-MTAB-25, E-GEOD-6919, ... (17 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-MTAB-62, ... (34 experiments)

Factor Value U/D Experiments
SW480
4
E-MEXP-1014, E-MTAB-37, E-GEOD-18005, E-GEOD-2509
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
MCF-7
2
E-GEOD-20081, E-GEOD-5823
MDA468
2
E-MEXP-440, E-MTAB-62
MOLT4
2
E-MTAB-37, E-MTAB-62
H1648
1
E-MTAB-62
409 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-120, E-GEOD-13909, E-GEOD-20677, ... (36 experiments)

Factor Value U/D Experiments
fibroblast
2
E-GEOD-3204, E-GEOD-3920
hematopoietic
1
E-GEOD-9894
monocyte
1
E-MEXP-2019
immortalised T lymphocytes
1
E-GEOD-13909
leydig cell
1
E-MTAB-25
T-ALL
1
E-GEOD-19069
58 more value(s).


Disease state

studied in E-GEOD-3307, E-TABM-15, E-GEOD-22148, E-MEXP-66, E-MTAB-62, ... (30 experiments)

Factor Value U/D Experiments
colon carcinoma
3
E-MTAB-62, E-MTAB-37, E-GEOD-3726
multiple myeloma
3
E-MTAB-62, E-GEOD-2113, E-GEOD-6691
acute quadriplegic myopathy
2
E-GEOD-3307, E-MTAB-62
choriocarcinoma
2
E-MTAB-37, E-MTAB-62
chordoma
1
E-MTAB-62
squamous cell carcinoma cell line, 8h after infection with fasX-mutant Streptococcus pyogenes
1
E-MTAB-62
124 more value(s).


Compound treatment

studied in E-MEXP-1269, E-GEOD-3284, E-GEOD-15205, E-GEOD-5824, E-GEOD-6400, ... (10 experiments)

Factor Value U/D Experiments
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
ethanol
1
E-MEXP-2241
unknown
1
E-GEOD-7307
TGF
1
1
E-GEOD-15205
rapamycin
1
E-GEOD-5824
bacterial endotoxin
1
1
E-GEOD-3284
10 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519


Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-21589, E-GEOD-16363

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Date of sample preparation and hybridisation
studied in E-GEOD-22541

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-MEXP-958, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-MTAB-69, E-GEOD-2509, E-GEOD-22148, E-GEOD-21138 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-17385, E-MTAB-108, E-MEXP-2340

Genotype
studied in E-GEOD-21750, E-TABM-321, E-GEOD-18005, E-GEOD-17347

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1220, E-GEOD-5681, E-GEOD-20504, E-GEOD-9764

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-16194, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-5764, E-GEOD-10433, E-GEOD-16363, ... (25 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-21750, E-GEOD-1460

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-19445, E-GEOD-1343

pt
studied in E-GEOD-21653

Qpcr egfr dct
studied in E-GEOD-5851

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-3697

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271

Processing time: 0.509 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM